Compare Corsair Gaming Inc (CRSR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs GSK plc — how do they compare? Corsair Gaming Inc trades at $13.64 (market cap $1.42B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 64.7× Corsair Gaming Inc's market cap, and GSK plc pays a 3.9% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and GSK plc for 93 Days on average.
| CRSR | GSK | |
|---|---|---|
Market Cap | $1.42B | $91.88B |
Volume | 1,160,938 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $14.35 | $61.18 |
52-Week Low | $4.58 | $43.24 |
Typical Hold Time | 25 Days | 93 Days |
Enterprise Value | $1.41B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.63, up 0.29% with a bullish technical signal. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.23 exceeding expectations by 228%. Recent product launches like the VOXARA microphone and strategic acquisitions demonstrate growth initiatives. Financials show improving cash flow trends with projected 2026 operating cash flow of $106 million, though net income margins remain thin at 2.53%.
CRSR presents a mixed outlook with strong earnings momentum and product innovation offset by valuation concerns at 42x P/E. Analyst consensus is cautious with 64% hold ratings and $12.40 price target below current levels. Key risks include competitive gaming peripherals market and execution of growth strategy. The stock's near-term direction hinges on Q3 earnings delivery and sustained margin improvement.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
